Ignite Creation Date:
2024-07-17 @ 10:44 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06500702
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-07-08
Brief Title:
A Study to Evaluate the Efficacy and Safety of Frexalimab SAR442970 or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Sponsor:
Sanofi
Organization:
Sanofi
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-09-04
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-12-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-02-16
Completion Date Type:
ESTIMATED
First Submit Date:
2024-07-08
First Submit QC Date:
None
Study First Post Date:
2024-07-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-09
Last Update Post Date:
2024-07-15
Last Update Post Date Type:
ESTIMATED